PDF
Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
Organization: United States Centers for Disease Control (CDC)Published: 2022
"Among children aged 5–11 years, local and systemic reactions were reported to v-safe with similar frequency after doses 2 and 3; specific reactions differed in severity. Vaccine administration errors were the most common events reported to the Vaccine Adverse Event Reporting System. No reports of myocarditis or death after receipt of dose 3 were received. Among children aged 5–11 years, serious adverse events after dose 3 are rare. Additional provider education might prevent vaccine administration errors." - Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
Additional Authors: Brandon Hugueley, Deborah Thompson, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Product Type: Report
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Specific Populations,Children,School-aged Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Specific Populations
Children
School-aged
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.